Navigation Links
REGURIN(R) XL (trospium chloride) Once Daily Tablets Now Available in the UK for the Treatment of Overactive Bladder
Date:9/7/2009

target='_new' href="http://www.specialityeuropeanpharma.com/" target="_new">http://www.specialityeuropeanpharma.com/)

Founded in April 2006, SEP is a privately owned speciality pharmaceutical company. Its mission is to become the leading Urologist focused specialty pharmaceutical business in Europe.

SEP owns worldwide rights to Plenaxis(R). Plenaxis is a novel product - it is the first in a new class of hormonal products (the GnRH blockers) and it is used to treat advanced and metastatic prostate cancer. Plenaxis has been launched in Germany and is going through the regulatory process in other EU countries.

SEP has distribution rights in certain European countries for two further products, Amphocil(R), an antifungal agent and Haemopressin(R), a product for the treatment of Bleeding Oesophageal Varices. Both of these products are delivered to clinicians in a hospital setting.

SEP has established its own commercial operations in the UK, Germany, France and Italy and will market its products in other regions and territories through relationships with expert partners.

About Rottapharm|Madaus

Established in 1961, Rottapharm is a multinational pharmaceutical company primarily engaged in the research, development and global distribution of new pharmaceutical products in different therapeutic areas including rheumatology, cardiology, gastroenterology, gynaecology paediatrics, dermatology, urology, oncology, bronchopneumology, psychiatry.

The Headquarter and main R&D site are located in Italy.

Rottapharm has recently acquired the global German pharmaceutical Group Madaus Pharma and today the Rottapharm|Madaus Group has subsidiaries or direct commercial operations throughout Europe and in the vast majority of Middle East, Asia (excluding Japan) and Central/South America countries.

Currently Rottapharm's main products include
'/>"/>

SOURCE Speciality European Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. FDA Approves Valcyte(R) (valganciclovir hydrochloride) to Prevent Cytomegalovirus (CMV) Disease in Pediatric Patients Who Receive Heart or Kidney Transplants
2. Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB)
3. New Data Presented at AUAs Annual Conference Prove GELNIQUE(TM) (oxybutynin chloride) 10% gel is an Effective, Safe Option for Female Overactive Bladder (OAB) Patients
4. MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine
5. FoodBizDaily.com Announces New Free Report - International Trade Opportunity: The Brazilian Acai Berry
6. Arcadia HealthCares DailyMed(TM) Signs Deal with Comfort Keepers(R), A Leading Provider of In-Home Care
7. Patents Issued Covering Stable Tablet Formulation and Once Daily Dosing Regimen for Kuvan
8. Intense Daily Workout May Keep Cancer at Bay
9. Life after chemotherapy: Daily tasks, quality of life may be affected, MU researcher finds
10. U.S. Census Bureau Daily Feature for July 21
11. FertilityAuthority Introduces E-Newsletter, The Daily Shot
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Newark, NJ (PRWEB) July 24, 2014 ... which will give one lucky family a rent-free week ... only until August 3, 2014. Don’t miss your chance ... The sweepstakes is open to all New Jersey residents, ... Horizon BCBSNJ Facebook page, http://www.facebook.com/HorizonBCBSNJ . , ...
(Date:7/24/2014)... with high-throughput data generated by breast cancer biologists ... computational method to determine how gene networks are ... as they respond to potential cancer therapy agents., ... each other in laboratory-grown cells is described in ... PLOS Computational Biology . , The method ...
(Date:7/24/2014)... Human Papillomavirus Vaccination (HPV) even after becoming sexually ... results than those who were never vaccinated. These ... Diseases . , Researchers from Boston University ... conducted a cross-sectional study of 235 women age ... HPV status and demographic and behavioral characteristics were ...
(Date:7/24/2014)... Los Angeles, CA (PRWEB) July 24, 2014 ... (FDA), American Optometric Association (AOA) and the Entertainment ... artists from the TV series American Horror Story ... to bring the dramatic realities of illegal ... public service campaign, which has already reached tens-of-thousands, ...
(Date:7/24/2014)... 4th Annual National Venous Interventional Summit is available ... an established Venous Endovascular Interventional Strategies group comprised ... is to provide a "How To" meeting for ... in advancing their knowledge and skills in venous ... own comprehensive venous interventional program. Topics at this ...
Breaking Medicine News(10 mins):Health News:(Beach) Sands of Time Running out to Enter Horizon Blue Cross Blue Shield of New Jersey’s 2014 “Back to the Boardwalk” Sweepstakes 2Health News:Gene changes in breast cancer cells pinpointed with new computational method 2Health News:Gene changes in breast cancer cells pinpointed with new computational method 3Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 2Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 3Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 4Health News:Preliminary agenda available for 4th VEINS Conference to be held October 9-12 in Chicago 2
... announced today that,the physicians of Great Lakes Radiologists, one of ... Aurora Medical Group. , ... and,clinics. , "These are ... care we provide for Aurora patients," said Jeff Bailet, M.D., ...
... and Management Realigned to Provide Full Support for Clinical ... Md., Dec. 15 EntreMed, Inc. (Nasdaq: ... to focus the Company,s resources on its most promising ... part of the Company,s overall plan to lower operating ...
... 15, 2008 Researchers from Yale University School ... magnification to standard white light colonoscopy in differentiating ... NBI was not more accurate than white light ... curve for these experienced endoscopists using NBI as ...
... brakes on killer disease, scientists say , , MONDAY, Dec. ... gene may provide a new target for treating deadly ... Mayo Clinic College of Medicine in Minnesota show the ... in another gene that, in a mutated form, has ...
... Imaging(R),Inc., a wholly owned subsidiary of Mercury Computer ... it has received FDA 510(k) clearance to market,its ... This release brings,significant enhancements to its prior offerings ... Neuroradiology and Oncology applications. The Neuro,option facilitates brain ...
... 15 Millennium Biotechnologies Group, Inc. (OTC Bulletin Board: ... in the Clinical and Sports Nutrition Market, announces financial results ... , Net revenue for the third ... in the third quarter 2007. The Company reduced its, ...
Cached Medicine News:Health News:Great Lakes Radiologists to Join Aurora Medical Group 2Health News:EntreMed Focuses on Development of ENMD-2076 2Health News:EntreMed Focuses on Development of ENMD-2076 3Health News:EntreMed Focuses on Development of ENMD-2076 4Health News:EntreMed Focuses on Development of ENMD-2076 5Health News:Narrow-band imaging comparable to white light colonoscopy in differentiating colorectal polyps 2Health News:Narrow-band imaging comparable to white light colonoscopy in differentiating colorectal polyps 3Health News:Narrow-band imaging comparable to white light colonoscopy in differentiating colorectal polyps 4Health News:Pancreatic Cancer May Have a New Foe 2Health News:Visage Imaging Receives FDA 510(k) Clearance for its Latest Thin Client Product Release 2Health News:Visage Imaging Receives FDA 510(k) Clearance for its Latest Thin Client Product Release 3Health News:Visage Imaging Receives FDA 510(k) Clearance for its Latest Thin Client Product Release 4Health News:Millennium Biotechnologies Reports Strong Third Quarter Revenue and Financial Results 2Health News:Millennium Biotechnologies Reports Strong Third Quarter Revenue and Financial Results 3
(Date:7/24/2014)... 2014  Perrigo Company (NYSE: PRGO ; ... therapeutic equivalent rating from the U.S. Food and Drug ... (NDA) for testosterone gel 1.0%. FDA concluded that Perrigo,s ... and can be substituted with the full expectation that ... profile as AndroGel 1% when used under the conditions ...
(Date:7/24/2014)... , July 24, 2014 Research ... "Machine Health Monitoring Market by Product, Component, Application and ... report to their offering. ... market is expected to witness a moderate growth as ... have almost reached the saturation levels. The ...
(Date:7/24/2014)... 24, 2014 /PRNewswire-iReach/ -- Delivery of the Report ... placed. Photo - http://photos.prnewswire.com/prnh/20140723/129707 ... in-depth market survey on Global and Chinese Hemodialysis ... information of Hemodialysis Machine including its classification, application ... and China,s top manufacturers of Hemodialysis Machine listing ...
Breaking Medicine Technology:Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 3Machine Health Monitoring (Vibration Monitoring, Thermography, Ultrasound Emission, Lubricating Oil Analysis, Corrosion Monitoring, Motor Current Signature Analysis) Market - Forecast to 2020 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 5
... patients can drive safely six weeks following surgical,treatment, ... most patients, pain levels are so low that they ... car again. A study published in the August,2008 issue ... http://www.jbjs.org/ ),also found that emergency brake time response in ...
... Calif., Aug. 26 XTENT, Inc.,(Nasdaq: XTNT ) ... CUSTOM II trial was published in the most recent ... the article was,Dr. Pieter R. Stella, M.D., of University ... CUSTOM II Investigators from 13 clinical,sites across Europe., ...
Cached Medicine Technology:Braking After Bunion Surgery 2Braking After Bunion Surgery 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 2XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 4
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
... glucose monitor elevates bedside glucose testing to ... approaches the quality of central laboratory testing. ... measuring strip technology. Current glucose strips ... Multi-Well system measures and corrects hematocrit interference ...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
... The BreatheX is a wearable CPAP ... treatment of sleep apnea. The lightweight BreatheX ... of therapy with its built-in, rechargeable battery, ... users will no longer need to be ...
Medicine Products: